Meir Medical Center
Kfar Saba, Israel
NCT Number: NCT00728611
to evaluate the influence of PRGF treatment on patient suffering from OA knee
Looking for future studies?
Notify Me40 year–75 year
All sexes
Interventional
Phase 2 / Phase 3
Kfar Saba, Israel
Autologous platelet-secreted growth factors (GFs) may have therapeutic effects in osteoarthritis (OA) capsular joints via multiple mechanisms. Our aim is to examine the effect of a platelet-derived preparation rich in growth factors (PRGFs) in OA knee
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
intra auricular injection 6mg
Other names: platelet-derived preparation rich in growth factors
20 mg / 2 ml
Other names: Arthrease
physiological water 3cc + lidocain 3cc
Other names: seline 0.9% nacl
Time frame: 1 year
Meir Medical Center
Other
PRP as a Treatment for Knee Osteoarthritis - Randomized-double-blind-placebo Control Trail.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07031518
Arthritis, Joint Diseases
Liège, Belgium
View Trial DetailsNCT07193368
Arthritis, Degenerative Joint Disease of the Knee
Ankara, Turkey (Türkiye)
View Trial DetailsNCT06588972
Arthritis, Joint Diseases
Foz do Iguaçu, Paraná, Brazil
View Trial DetailsNCT06927934
Arthralgia, Arthritis
Kyiv, Ukraine
View Trial Details